Please login to the form below

Not currently logged in
Email:
Password:

betrixaban

This page shows the latest betrixaban news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’ osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS)

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa. ... Moreover, the CHMP still have concerns about betrixaban that will continue to delay approval, even though it has already been approved by the US FDA as

  • Merck collaborate over betrixaban

    Merck and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for betrixaban. ... for additional royalties and to co-promote betrixaban with Merck in the US.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Promising phase II results of betrixaban for VTE

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics